Compound scale-up at the discovery-development interface.
As a result of an economically challenging environment within the pharmaceutical industry, pharmaceutical companies and their departments must increase productivity and cut costs to stay in line with the market. Discovery-led departments such as the medicinal chemistry and lead optimization groups focus on synthesizing large varieties of compounds in minimal amounts, while the chemical development groups must then deliver a few chosen leads employing an optimized synthesis method and using multi-kilogram quantities of material. A research group at the discovery-development interface has the task of medium-scale synthesis which is important in the lead selection stage. The primary objective of this group is the initial scale-up of promising leads for extensive physicochemical and biological testing. The challenge of the interface group involves overcoming synthetic issues within the rigid, accelerated timelines.
Nikitenko
Antonia A
AA
Chemical and Screening Sciences, Discovery Synthetic Chemistry, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA. nikitea@wyeth.com
D035843:Biomedical Research / Q000191:economics / Q000458:organization & administration / Q000639:trends; D003659:Decision Making, Organizational; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration* / Q000639:trends; D006801:Humans; D015394:Molecular Structure; D004364:Pharmaceutical Preparations / Q000737:chemistry / Q000191:economics; D013997:Time Factors
D004364:Pharmaceutical Preparations